The role of third-generation beta-blocking agents in chronic heart failure

Michael R. Bristow, Robert L. Roden, Brian D. Lowes, Edward M. Gilbert, Eric J. Eichhorn

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Third-generation beta-blocking agents developed for the hypertension marked are proving useful in the treatment of chronic heart failure (HF). These compounds share the ancillary property of vasodilation, which improves acute tolerability by unloading the failing left ventricle at a time when beta-adrenergic produces myocardial depression. In the case of carvedilol and bucindolol, this allows for the administration of nonselective beta blockade. Because of blockade of both β1 and β2 adrenergic receptors as well as other properties, these compounds possess a more comprehensive antiadrenergic profile than second-generation, β1-selective compounds. For this and potentially other reasons, this-generation beta-blocking agents have theoretical efficacy advantages that have yet to be demonstrated in large- scale trials. Ongoing trials with either second- or third-generation compounds and one trial directly comparing a compound from each class will provide the answer as to whether third-generation compounds have an advantage in the treatment of chronic HF.

Original languageEnglish (US)
Pages (from-to)I3-I13
JournalClinical Cardiology
Volume21
Issue number12 SUPPL. 1
StatePublished - Dec 1 1998

Fingerprint

Heart Failure
Adrenergic Antagonists
Vasodilation
Adrenergic Agents
Adrenergic Receptors
Heart Ventricles
Hypertension
bucindolol
carvedilol

Keywords

  • Adrenergic nervous system
  • Beta-blocking agents
  • Heart failure
  • Third- generation beta-blocking agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bristow, M. R., Roden, R. L., Lowes, B. D., Gilbert, E. M., & Eichhorn, E. J. (1998). The role of third-generation beta-blocking agents in chronic heart failure. Clinical Cardiology, 21(12 SUPPL. 1), I3-I13.

The role of third-generation beta-blocking agents in chronic heart failure. / Bristow, Michael R.; Roden, Robert L.; Lowes, Brian D.; Gilbert, Edward M.; Eichhorn, Eric J.

In: Clinical Cardiology, Vol. 21, No. 12 SUPPL. 1, 01.12.1998, p. I3-I13.

Research output: Contribution to journalArticle

Bristow, MR, Roden, RL, Lowes, BD, Gilbert, EM & Eichhorn, EJ 1998, 'The role of third-generation beta-blocking agents in chronic heart failure', Clinical Cardiology, vol. 21, no. 12 SUPPL. 1, pp. I3-I13.
Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clinical Cardiology. 1998 Dec 1;21(12 SUPPL. 1):I3-I13.
Bristow, Michael R. ; Roden, Robert L. ; Lowes, Brian D. ; Gilbert, Edward M. ; Eichhorn, Eric J. / The role of third-generation beta-blocking agents in chronic heart failure. In: Clinical Cardiology. 1998 ; Vol. 21, No. 12 SUPPL. 1. pp. I3-I13.
@article{b6228d933e5d470c9e45540ab08fcf8f,
title = "The role of third-generation beta-blocking agents in chronic heart failure",
abstract = "Third-generation beta-blocking agents developed for the hypertension marked are proving useful in the treatment of chronic heart failure (HF). These compounds share the ancillary property of vasodilation, which improves acute tolerability by unloading the failing left ventricle at a time when beta-adrenergic produces myocardial depression. In the case of carvedilol and bucindolol, this allows for the administration of nonselective beta blockade. Because of blockade of both β1 and β2 adrenergic receptors as well as other properties, these compounds possess a more comprehensive antiadrenergic profile than second-generation, β1-selective compounds. For this and potentially other reasons, this-generation beta-blocking agents have theoretical efficacy advantages that have yet to be demonstrated in large- scale trials. Ongoing trials with either second- or third-generation compounds and one trial directly comparing a compound from each class will provide the answer as to whether third-generation compounds have an advantage in the treatment of chronic HF.",
keywords = "Adrenergic nervous system, Beta-blocking agents, Heart failure, Third- generation beta-blocking agents",
author = "Bristow, {Michael R.} and Roden, {Robert L.} and Lowes, {Brian D.} and Gilbert, {Edward M.} and Eichhorn, {Eric J.}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "21",
pages = "I3--I13",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "12 SUPPL. 1",

}

TY - JOUR

T1 - The role of third-generation beta-blocking agents in chronic heart failure

AU - Bristow, Michael R.

AU - Roden, Robert L.

AU - Lowes, Brian D.

AU - Gilbert, Edward M.

AU - Eichhorn, Eric J.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Third-generation beta-blocking agents developed for the hypertension marked are proving useful in the treatment of chronic heart failure (HF). These compounds share the ancillary property of vasodilation, which improves acute tolerability by unloading the failing left ventricle at a time when beta-adrenergic produces myocardial depression. In the case of carvedilol and bucindolol, this allows for the administration of nonselective beta blockade. Because of blockade of both β1 and β2 adrenergic receptors as well as other properties, these compounds possess a more comprehensive antiadrenergic profile than second-generation, β1-selective compounds. For this and potentially other reasons, this-generation beta-blocking agents have theoretical efficacy advantages that have yet to be demonstrated in large- scale trials. Ongoing trials with either second- or third-generation compounds and one trial directly comparing a compound from each class will provide the answer as to whether third-generation compounds have an advantage in the treatment of chronic HF.

AB - Third-generation beta-blocking agents developed for the hypertension marked are proving useful in the treatment of chronic heart failure (HF). These compounds share the ancillary property of vasodilation, which improves acute tolerability by unloading the failing left ventricle at a time when beta-adrenergic produces myocardial depression. In the case of carvedilol and bucindolol, this allows for the administration of nonselective beta blockade. Because of blockade of both β1 and β2 adrenergic receptors as well as other properties, these compounds possess a more comprehensive antiadrenergic profile than second-generation, β1-selective compounds. For this and potentially other reasons, this-generation beta-blocking agents have theoretical efficacy advantages that have yet to be demonstrated in large- scale trials. Ongoing trials with either second- or third-generation compounds and one trial directly comparing a compound from each class will provide the answer as to whether third-generation compounds have an advantage in the treatment of chronic HF.

KW - Adrenergic nervous system

KW - Beta-blocking agents

KW - Heart failure

KW - Third- generation beta-blocking agents

UR - http://www.scopus.com/inward/record.url?scp=0031760650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031760650&partnerID=8YFLogxK

M3 - Article

C2 - 9853189

AN - SCOPUS:0031760650

VL - 21

SP - I3-I13

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 12 SUPPL. 1

ER -